Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
News on the Molecular Biology of Aging
7 January 2002. P53 misregulation and cancer have become almost synonymous in the scientist's imagination. Mutations in this prominent tumor suppressor gene have been found in the majority of human cancers, and downregulating the protein increases tumor incidence in animal models. P53 can halt cell division and induce DNA repair in response to stress and trigger cell death if the cell is beyond repair. One would think, then, that upregulating this protective protein could treat cancers, and therapies to that effect are being developed. The only trouble, according to a report in last Thursday's Nature10, is that too much p53 may accelerate aging.

Larry Donehauer of the Baylor College of Medicine in Houston, Texas, and colleagues at several other institutions report that they have, by mistake, created a mutant mouse that overproduces p53. The reason for the overproduction appears to be that one of the two alleles is considerably shortened and induces its normal counterpart to overproduce the protein. As expected, these mice are more resistant to tumors, but rather than living longer, their life spans were only about 80 percent that of their wildtype littermates. This surprising finding is accompanied by numerous signs of early aging, including osteoporosis, generalized organ atrophy, and diminished stress tolerance.

"The influence of p53 on life span may result from a delicate balance between its antitumour and pro-ageing effects, such that too little p53 increases mortality from cancer whereas too much p53 increases mortality," write Gerardo Ferbeyre of Universite de Montreal in Canada and Scott Lowe of Coldspring Harbor Laboratory in New York in an accompanying News and Views article. They add, "The results raise the disturbing possibility that the DNA-damaging drugs used to treat cancer in young people might prompt p53 into action and accelerate age-related disorders later on."

. . . And of Coenzyme Q

A molecule that is better known in conjunction with aging is coenzyme Q (Q). The enzyme, from both endogenous and dietary sources, is an important player in maintaining the proton gradient across the mitochondrial membrane that drives ATP synthesis. One of the byproducts of this movement of charged particles is the production of reactive oxygen species (ROSs), free radicals that have been linked to aging in general and the destruction of cells in particular. In the current issue of Science, Paula Larsen and Catherine Clarke of the University of California, Los Angeles, show that removing Q from the diet of normal nematodes (Caenorhabditis elegans) dramatically extends their life spans.

The study extends work showing that dietary Q could rescue worms genetically altered to block the production of endogenous Q, allowing them to develop normally and live longer. The researchers wanted to avoid interfering with normal larval development, which depends on Q, in order to isolate the effects of reduced Q on adult aging. They found that wildtype nematodes fed a Q-less diet beginning in adulthood lived approximately 60 percent longer. The data support a model whereby a mitochondrial membrane protein gradient deprived of dietary Q, relying solely on endogenous sources, will produce fewer ROSs. This in turn could help slow aging. Larsen and Clarke also show that they can further extend the life of several nematode mutants (clk-1, daf-2, daf-12, daf-16), which already live longer than wildtype nematodes. They authors suggest that this additive effect on longevity may result from reduced ROS production combined with increased breakdown of ROS.

"I think the article is very interesting," said nematode aging expert Cynthia Kenyon of the University of California, San Francisco. "It will also be interesting to learn how, at the molecular level, this extension of lifespan occurs." An accompanying News and Views article discusses how the paper points to interactions in the mitochondrion between Q and the insulin signaling pathway.-Hakon Heimer.

Reference:Tyner S et al. P53 mutant mice that display early ageing-associated phenotypes. Nature 2002 Jan 3;415:46-51. Abstract

Ferbeyre G, Lowe SW. The price of tumour suppression? Nature 2002 Jan 3;415:26-7. Abstract

Larsen PL, Clarke CF. Extension of life span in Caenorhabditis elegans by a diet lacking coenzyme Q. Science 2002 Jan 4;295:120-3. Abstract

Tatar M, Rand DM. Dietary advice on Q. Science. 4 Jan 2002;295. Abstract

 
Comments on News and Primary Papers
  Comment by:  Leonard Guarente
Submitted 7 January 2002  |  Permalink Posted 7 January 2002

I find the study interesting because our work suggests that SIR2 will be a universal regulator of aging (definitely in yeast and worms) and we recently found that it functions as a negative regulator of p53 in mammalian cells. My hunch is that this is only one of several relevant SIR2 activities that may impact aging. This paper shows that up-regulation of p53 in a whole mouse can elicit symptoms that are aging-like. One hopes there is a window in which SIR2 can be up-regulated (pharmacologically?) to slow aging without increasing cancer. One cautionary note—it is always difficult to say that a mutant phenotype is premature aging rather than pathology. It is much more convincing to make the organism live longer by genetic intervention.

View all comments by Leonard Guarente

  Comment by:  Gemma Casadesus, Jim Joseph, George Perry, ARF Advisor (Disclosure), Mark A. Smith (Disclosure)
Submitted 7 January 2002  |  Permalink Posted 7 January 2002

Homeostatic Control: Relevance to Alzheimer Disease
Larsen and Clarke highlight that endogenous homeostatic control over energetics and endogenous antioxidant defenses make cells and organisms better adapted to survival than exogenous intervention. These authors show that Caenorhabditis elegans deprived of exogenous Coenzyme Q (CoQ) have an extended life span over those replete with endogenous CoQ provided by biosynthesis plus external food-derived CoQ. Genetic manifestations of food sources and worms shows that the life span extension is specific to exogenous CoQ restriction, even though exogenous CoQ is required to complete the life cycle/development of worms unable to synthesize it. The authors and attached commentary (Tatar and Rand, 2002) interpret the effect through signaling or oxidative stress, but an additional consideration is the...  Read more
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad